Skip to main content
Print Save

Uloric Disease Interactions

There are 4 disease interactions with Uloric (febuxostat).

Major

Antihyperuricemic agents (applies to Uloric) secondary hyperuricemia

Major Potential Hazard, Moderate plausibility. Applicable conditions: Tumor Lysis Syndrome, Lesch-Nyhan Syndrome, Organ Transplant

No studies with febuxostat or lesinurad have been conducted in patients with secondary hyperuricemia (including organ transplant recipients). The use of these drugs is contraindicated in patients where the uric acid formation is greatly increased, such as patients with malignant disease, tumor lysis syndrome or Lesch-Nyhan syndrome.

References

  1. "Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America (2009):
  2. "Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals (2015):
Moderate

Antihyperuricemic agents (applies to Uloric) CV disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease

Major adverse cardiovascular events (cardiovascular deaths, non- fatal myocardial infarctions and non- fatal strokes), were reported during clinical trials with some antihyperuricemic agents, such as febuxostat and lesinurad. Although a causal relationship has not been established, caution is advised when used in patients with cardiovascular disease. Monitoring for signs or symptoms of myocardial infarction or stroke is recommended.

References

  1. "Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America (2009):
  2. "Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals (2015):
Moderate

Febuxostat (applies to Uloric) renal dysfunction

Moderate Potential Hazard, Moderate plausibility.

There are insufficient data on the use of febuxostat in patients with severe renal impairment (ClCr less than 30 mL/min), therefore caution should be exercised on these patients. No dose adjustment is needed in patients with mild or moderate renal impairment.

References

  1. "Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America (2009):
Moderate

Febuxostat/lesinurad (applies to Uloric) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

No studies have been conducted in patients with severe hepatic impairment (Child-Pugh Class C), therefore caution should be exercised if using febuxostat or lesinurad on these patients. No dose adjustment is necessary in patients with mild or moderate hepatic impairment.

References

  1. "Product Information. Uloric (febuxostat)." Takeda Pharmaceuticals America (2009):
  2. "Product Information. Zurampic (lesinurad)." Astra-Zeneca Pharmaceuticals (2015):

Uloric drug interactions

There are 38 drug interactions with Uloric (febuxostat).

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer